Department of Gastroenterology, University Hospital CHU of Liège, Belgium.
Department of Medicine, Section of Gastroenterology, Lovisenberg Diaconal Hospital, Oslo, Norway.
Dig Liver Dis. 2017 Sep;49(9):991-996. doi: 10.1016/j.dld.2017.05.009. Epub 2017 May 19.
The aim of our work was to test the usability of fecal calprotectin (FC) home-based test in inflammatory bowel disease (IBD) patients.
IBD patients were prospectively recruited. They had to measure FC with a dedicated tool and smartphone application, 5 times at two weeks intervals over an 8 weeks period. They had to fill in a usability questionnaire at the first and the last FC measurement. A System Usability Scale (SUS: 0-100) and the Global Score of Usability (GSU: 0-85) were calculated. FC was also centrally measured by ELISA.
Fifty-eight patients were recruited. Forty-two performed at least one FC measurement and 27 performed all the FC requested measurements. The median (IQR) SUS (0-100) at the first and last use were 85 (78-90) and 81 (70-88), respectively; the median (IQR) GSU (0-85) at the first and last use were 74 (69-80) and 77 (68-83), respectively. Adherence to the planned measurements and usability of the tool were higher in females and in less severe disease. The intra-class correlation coefficient between home-based and centrally measured FC was 0.88.
The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC by ELISA.
本研究旨在测试粪便钙卫蛋白(FC)家用检测在炎症性肠病(IBD)患者中的可用性。
本研究前瞻性招募了 IBD 患者。他们需使用专用工具和智能手机应用程序,在 8 周内每两周测量 FC 5 次。他们需在首次和最后一次 FC 测量时填写一份使用情况调查问卷。计算系统可用性量表(SUS:0-100)和总体可用性得分(GSU:0-85)。FC 也由 ELISA 中心测量。
共招募了 58 名患者。其中 42 名患者至少进行了一次 FC 测量,27 名患者完成了所有要求的 FC 测量。首次和末次使用时的中位数(IQR)SUS(0-100)分别为 85(78-90)和 81(70-88);首次和末次使用时的中位数(IQR)GSU(0-85)分别为 74(69-80)和 77(68-83)。女性和疾病较轻的患者对计划测量的依从性和工具的可用性更高。家用和中心测量 FC 之间的组内相关系数为 0.88。
家用 FC 测量的依从性尚可。家用检测的可用性评分较高。与 ELISA 中心测量的 FC 相关性良好。